Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
FDA expanded EVO/EVO+ age indication, preliminary Q1 sales exceeded $90M with China rebound and Americas growth, Q1 results due 2026-05-13, and shares remain up about 32% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Quarterly turnaround ⢠Strong liquidity ⢠Earnings volatility STAA's quarterly turnaround, strong liquidity, and positive cash flow are encouraging, but elevated valuation and volatile annual profitability warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Bearish stabilization ⢠$22.11 rebound ⢠$24.10 resistance Support Level: $22.11â$22.60 Resistance Level: $23.58â$24.10 STAA is stabilizing after last month's 3% decline, but remains bearish below its moving average unless it breaks above $24.10; watch $22.11 for renewed downside risk.
Sentiment & News
Key News Insights: ⢠China Sales Surge ⢠Earnings Beat ⢠Platform Expansion STAAR's earnings beat and China-led growth strengthen its outlook, though diversification efforts remain key.
AI Summary
STAAR's cash-generative return to profitability is credible, but the investment has shifted into a China-concentration test: with 56% of sales and nearly all growth coming from China, investors should require sustained ex-China acceleration and clean working-capital conversion before underwriting its premium valuation.
Description
STAAR Surgical Company designs, manufactures and sells implantable intraocular lenses and the delivery systems used to place them, along with preloaded cataract lenses, injector components and related surgical instruments. Its products, which address refractive errors and cataract treatment, are marketed primarily to ophthalmologists and surgical centers through a mix of direct sales forces and distributor networks across North America, Europe and Asia. The company was founded in 1982 and is headquartered in Lake Forest, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | STAA | STAAR Surgical Company | FDA expanded EVO/EVO+ age indication, preliminary Q1 sales exceeded $90M with China rebound and Americas growth, Q1 results due 2026-05-13, and shares remain up about 32% over 21 trading days. | Closed | +5.9% |
| Apr 10 | Apr 17 | STAA | STAAR Surgical Company | STAAR Surgical has a fresh revenue surprise and momentum: preâannounced Q1 net sales above ~$90M drove a ~25% twoâday spike, and FDA expansion of EVO/EVO+ ICL indication (21â60 years) broadens its market. Shares are ~42% above their 21âday mean, with strong volume and activist/institutional buying, making STAA a highâvelocity nearâterm trade around the formal earnings release. | Closed | -5.1% |